4SC to Present at the 12th Annual Bio CEO and Investor Conference

4SC AG (Frankfurt, Prime Standard: VSC) a drug discovery and development company focused on autoimmune and cancer indications, today announced that Ulrich Dauer, CEO, will present an update on the company's strategy, programmes and prospects at the 12th Annual Bio CEO and Investor Conference in New York, USA, on Monday, 8th February at 4.00pm EST/10.00pm CET.

A webcast of the presentation will be available at:

http://www.veracast.com/webcasts/bio/ceoinvestor2010/86114242.cfm

Notes to Editor

About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. 4SC-101, a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's lymphoma. 4SC-203, a further oncology compound, is in a Phase I study. 4SC-205 is due to commence a Phase I study shortly. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

4SC was founded in 1997, has 93 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

For further information please visit www.4sc.com.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.